As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...
There aren’t a lot of easy changes the drugmaker can make to right itself quickly. Boosting sales fast enough to lift shares will be hard, and high debts rule out a game-changing acquisition. Get the ...